罗沙司他对南疆腹透患者肾性贫血的疗效评价

姗姗 周(喀什地区第一人民医院肾病内科，中国)
培仑 李(喀什地区第一人民医院肾病内科，中国)
转福 王(喀什地区第一人民医院肾病内科，中国)
妮热 穆(喀什地区第一人民医院肾病内科，中国)
(喀什地区第一人民医院肾病内科，中国)
卜力孜 阿(喀什地区第一人民医院肾病内科，中国)
斌斌 余(喀什地区第一人民医院肾病内科，中国)

摘要

目的：评估罗沙司他与重组人促红素（rhEPO）治疗腹膜透析（PD）患者肾性贫血的有效性及安全性。方法：将60例PD肾性贫血患者随机分为罗沙司他组（n=30）和rhEPO组（n=30），两组均联合多糖铁复合物治疗3个月，比较两组治疗前后贫血指标（Hb、RBC、Hct）、铁代谢指标（Fe、TIBC、TSAT）、脂代谢指标（TC、TG、HDL、LDL）、炎症指标（CRP、IL-6）的变化及不良反应发生情况。结果：两组基线资料相比无显著性差异（P＞0.05），治疗后两组Hb、RBC、Hct均较前显著改善（P＜0.05），罗沙司他组增幅更大（P＜0.05）。罗沙司他组Fe、SF、TIBC较治疗前明显改善，其TC、LDL、IL-6较治疗前同样显著降低（P＜0.05），且不良反应发生率低于rhEPO 组（3% vs 7%, P<0.05）。讨论：相较于rhEPO，罗沙司他能更有效地改善PD患者贫血和铁代谢，在所纳入样本中观察到炎症指标下降，还可改善脂代谢，安全性更优。

关键词

肾性贫血；腹膜透析；罗沙司他；重组人促红素

参考

Fishbane S, Coyne DW. How I treat renal anemia. Blood. 2020;136(7):783-789.

Ni Z, Jin H, Jiang G, et al. A Telemedicine-Based Registration System for the Management of Renal Anemia in Patients on Maintenance Hemodialysis: Multicenter Study. J Med Internet Res. 2019;21(5):e13168.

Shen Y, Wang J, Yuan J, et al. Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2021;22(1):64.

郭亚东,殷淑惠,徐天华等.腹膜透析患者贫血现状及其影响因素[J].中华肾脏病杂志,2024,40(04):330-334.

Sugahara M, Tanaka T, Nangaku M. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. Pharmacol Ther. 2022;239:108272.

Yang Z, Ma T, Xu X, et al. Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis. Kidney Int Rep. 2021;7(3):455-464. Published 2021 Dec 27.

Hou YP, Mao XY, Wang C, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial. J Formos Med Assoc. 2022;121(2):529-538.

Liu J, Li S, Yang F, et al. A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness. Korean J Intern Med. 2024;39(3):488-500.

Matsuoka T, Abe M, Kobayashi H. Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction. Int J Mol Sci. 2024;25(7):3745. Published 2024 Mar 27.

张萌娜,朱慧琪.C反应蛋白/白蛋白比值与糖尿病肾病患者贫血发生的关系[J].新疆医学,2024,54(06):693-696+709.

Ganz T, Locatelli F, Arici M, Akizawa T, Reusch M. Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease. J Clin Med. 2023;12(13):4217.

Nakanishi T, Kimura T, Kuragano T. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease. Contrib Nephrol. 2019;198:124-134.

Zhao H, Li P, Zhang HL,et al. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease. Ren Fail. 2023;45(2):2258986.

Sakaguchi Y, Hamano T, Wada A, et al. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol. 2019;30(6):1037-1048.

Liu J, Zhang A, Hayden JC, et al. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis. Pharmacol Res. 2020;155:104747.

Akizawa T, Otsuka T, Reusch M, et al. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. Ther Apher Dial. 2020 Apr;24(2):115-125.

Zhu XW, Zhang CX, Xu TH,et al. Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia. World J Clin Cases. 2021;9(26):7682-7692.

Ganz T. Anemia of Inflammation. N Engl J Med. 2019;381(12):1148-1157.

Yan Z, Xu G. A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat. Front Med (Lausanne). 2020;7:393.

Zhao XN, Liu SX, Wang ZZ,et al. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria. Eur J Med Res. 2023;28(1):230.

Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. J Am Soc Nephrol. 2022;33(4):850-866.

Suh SH, Kim SW. Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview. Diabetes Metab J. 2023;47(5):612-629.

Wu T, Qi Y, Ma S, et al. Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis. Ren Fail. 2022;44(1):529-540.

Xu T, Ruan Y, Liu N, et al. Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia. Ren Fail. 2025;47(1):2460726.

Tsubakihara Y, Akizawa T, Nangaku M, et al. A 24-week anemia correction study of daprodustat in Japanese dialysis patients[J]. Ther Apher Dial, 2020,24(2):108-114.

Hwang S, Nguyen AD, Jo Y,et al. Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem.2017;292(22):9382-9393.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v9i4.38104